Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

(2014) M. E. Elez et al.   CLINICAL CANCER RESEARCH

Combination Treatment With Trabectedin and Irinotecan or Topotecan Has Synergistic Effects Against Ovarian Clear Cell Carcinoma Cells

(2014) Mahiru Kawano et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary

(2014) Tomoyuki Sasano et al.   MOLECULAR CANCER RESEARCH

Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

(2013) Michela Romano et al.   INTERNATIONAL JOURNAL OF CANCER

Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

(2013) T. Hisamatsu et al.   MOLECULAR CANCER THERAPEUTICS

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

(2012) A. Vidal et al.   CLINICAL CANCER RESEARCH

The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary

(2011) S. Mabuchi et al.   CLINICAL CANCER RESEARCH

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

(2011) D. G. Soares et al.   MOLECULAR CANCER THERAPEUTICS

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy

(2010) Aristotle Bamias et al.   CANCER

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

(2009) S. Mabuchi et al.   CLINICAL CANCER RESEARCH

DNA Damage, Aging, and Cancer

(2009) Jan H.J. Hoeijmakers   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

(2008) J. R. Molina et al.   CLINICAL CANCER RESEARCH